JENNIFER A WOYACH ET AL: "2894 Final Results of a Phase I Study of the Fc Engineered CD19 Antibody XmAb(R)5574 (MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", INTERNET CITATION, [Online] 9 December 2012 (2012-12-09), page 1, XP002737890, Retrieved from the Internet: URL:https://ash.confex.com/ash/2012/webpro gram/Paper51418.html> [retrieved on 2015-03-27] (B1)

Joseph A Fraietta ET AL: "Regular Article IMMUNOBIOLOGY Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia", Blood, 1 January 2016 (2016-01-01), XP55287883, DOI: 10.1182/blood-2015-11- Retrieved from the Internet: URL:http://www.bloodjournal.org/content/12 7/9/1117.full.pdf (B1)

M RUELLA: "COMBINATION OF IBRUTINIB AND ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF RELAPSING/REFRACTORY MANTLE CELL LYMPHOMA (MCL)", 20TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION, JUN 11-14, 2015, VIENNA, AUSTRIA, 13 June 2015 (2015-06-13), pages 1-1, XP55281361, (B1)

MEI WU ET AL: "Novel agents for chronic lymphocytic leukemia", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, vol. 6, no. 1, 16 May 2013 (2013-05-16), page 36, XP021151589, ISSN: 1756-8722, DOI: 10.1186/1756-8722-6-36 (B1)

WOYACH J A ET AL: "A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 124, no. 24, 4 December 2014 (2014-12-04), pages 3553-3560, XP002737891, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2014-08-593269 [retrieved on 2014-10-09] (B1)

Ohio State University: "Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL - Full Text View - ClinicalTrials.gov", , 7 October 2010 (2010-10-07), XP55287928, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/st udy/NCT01217749?term=NCT01217749&rank=1 [retrieved on 2016-07-12] (B1)

TADEUSZ ROBAK ET AL: "Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia", SEMINARS IN ONCOLOGY, vol. 43, no. 2, 1 April 2016 (2016-04-01), pages 280-290, XP055287899, US ISSN: 0093-7754, DOI: 10.1053/j.seminoncol.2016.02.010 (B1)

WO-A1-2013/024097 (B1)

Morphosys Ag: "Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib in R/R CLL/SLL Patients Pretreated With BTKi - Full Text View - ClinicalTrials.gov", ClinicalTrials.ogv, 15 December 2015 (2015-12-15), XP55287895, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NC T02639910?term=mor00208+AND+ibrutinib&rank =1 [retrieved on 2016-07-12] (B1)